afimetoran   Click here for help

GtoPdb Ligand ID: 14751

Synonyms: BMS-986256 | BMS986256 | example 15 [US10478424]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Afimetoran (BMS-986256) is an orally bioavailable, small molecule, dual Toll-like receptor 7 and 8 (TLR7/8) antagonist [1]. It was designed as an immunomodulator for the treatment of inflammation and autoimmune diseases [3]. Afimetoran may also bind to the TLR adaptor protein toll-interacting protein (TOLLIP) [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 86.32
Molecular weight 444.57
XLogP 2.04
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(C)C1=C(C2=CN3C(=NC=N3)C(=C2C)C)NC4=C1C=C(C=C4)C5CCN(CC5)CC(=O)N
Isomeric SMILES O=C(CN1CCC(CC1)C2=CC=C3NC(C4=CN5N=CN=C5C(C)=C4C)=C(C(C)C)C3=C2)N
InChI InChI=1S/C26H32N6O/c1-15(2)24-20-11-19(18-7-9-31(10-8-18)13-23(27)33)5-6-22(20)30-25(24)21-12-32-26(28-14-29-32)17(4)16(21)3/h5-6,11-12,14-15,18,30H,7-10,13H2,1-4H3,(H2,27,33)
InChI Key SNFVHLQYHFQOEP-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Dyckman AJ, Dodd DS, Mussari CP, Pasunoori L, Kumar SR. (2019)
[1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds.
Patent number: US10478424B2. Assignee: Syngene International Ltd, Bristol Myers Squibb Co. Priority date: 23/07/2018. Publication date: 19/11/2019.
2. Habib O, Ishaq S, Habib K, Khattak A, Yang W, Li Z, Bukhari K, Ullah A, Ahmad A, Ali Q. (2025)
Structural and immunological impacts of TOLLIP nsSNPs: A computational biology approach to drug discovery and immune system modulation.
PLoS One, 20 (11): e0328573. [PMID:41231851]
3. Hosein F, Ignatenko S, Chadwick KD, Zhu L, Baribaud F, Saini J, Bach T, Aras U, Zhang W, Karabeber H et al.. (2025)
Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Afimetoran, a Toll-Like Receptor 7 and 8 Inhibitor, in Patients With Cutaneous Lupus Erythematosus: A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study.
ACR Open Rheumatol, 7 (7): e70059. [PMID:40568766]